2026-2034年全球青光眼市場規模、佔有率、趨勢和成長分析報告

預計青光眼市場將從 2025 年的 98.6 億美元成長到 2034 年的 151.2 億美元，2026 年至 2034 年的複合年成長率為 4.87%。

由於與老齡化相關的眼科疾病盛行率不斷上升以及全球老年人口的持續成長，全球青光眼市場正經歷持續成長。人們對早期檢測和治療方案的認知不斷提高，促使更多患者在適當的時候尋求醫療協助。診斷技術的進步和篩檢計畫的改進也推動了青光眼治療方法和管理方案需求的成長。

關鍵成長要素包括新藥製劑的研發、微創青光眼手術 (MIGS) 以及能夠提高患者依從性的持續治療方案。製藥公司和醫療設備製造商不斷增加的研發投入正在加速創新。此外，新興市場眼科醫療服務可近性的提高正在擴大患者群體，並支持整體市場成長。

展望未來，診斷影像技術與人工智慧（AI）篩檢工具的融合有望推動市場發展。聯合療法和個人化治療方案的日益普及有望促進市場長期成長。隨著醫療體係日益重視眼科預防保健和早期療育策略，全球青光眼市場有望實現穩定永續成長。

目錄

第1章：引言

第2章執行摘要

第3章 市場變數、趨勢與框架

• 市場譜系展望
• 滲透率和成長前景分析
• 價值鏈分析
• 法律規範
  • 標準與合規性
  • 監管影響分析
• 市場動態
  • 市場促進因素
  • 市場限制因素
  • 市場機遇
  • 市場挑戰
• 波特五力分析
• PESTLE分析

第4章 全球青光眼市場：依疾病類型分類

• 市場分析、洞察與預測
• 開放性青光眼
• 隅角閉鎖性青光眼
• 其他

第5章 全球青光眼市場：依藥物類別分類

• 市場分析、洞察與預測
• 前列腺素類似物
• BETA阻斷劑
• 腎上腺素能促效劑
• 碳酸酐酶抑制劑
• 其他

第6章 全球青光眼市場：依通路分類

• 市場分析、洞察與預測
• 醫院藥房
• 零售藥房
• 網路藥房

第7章 全球青光眼市場：按地區分類

• 區域分析
• 北美市場分析、洞察與預測
  • 美國
  • 加拿大
  • 墨西哥
• 歐洲市場分析、洞察與預測
  • 英國
  • 法國
  • 德國
  • 義大利
  • 俄羅斯
  • 其他歐洲國家
• 亞太市場分析、洞察與預測
  • 印度
  • 日本
  • 韓國
  • 澳洲
  • 東南亞
  • 其他亞太國家
• 拉丁美洲市場分析、洞察與預測
  • 巴西
  • 阿根廷
  • 秘魯
  • 智利
  • 其他拉丁美洲國家
• 中東和非洲市場分析、洞察與預測
  • 沙烏地阿拉伯
  • UAE
  • 以色列
  • 南非
  • 其他中東和非洲國家

第8章 競爭情勢

• 最新趨勢
• 公司分類
• 供應鏈和銷售管道合作夥伴（根據現有資訊）
• 市場佔有率和市場定位分析（基於現有資訊）
• 供應商情況（基於現有資訊）
• 策略規劃

第9章：公司簡介

• 主要公司的市佔率分析
• 公司簡介
  • Pfizer Inc
  • Santen Pharmaceutical Co. Ltd
  • Novartis AG
  • Alcon Inc
  • Akron Operating Company LLC
  • Thea Pharma
  • AbbVie Inc
  • Bausch+Lomb Corporation
  • Teva Pharmaceutical Industries Ltd
  • Aerie Pharmaceuticals

The Glaucoma Market size is expected to reach USD 15.12 Billion in 2034 from USD 9.86 Billion (2025) growing at a CAGR of 4.87% during 2026-2034.

The Global Glaucoma Market is experiencing sustained growth due to the increasing prevalence of age-related eye disorders and the expanding geriatric population worldwide. Rising awareness about early detection and treatment options is encouraging more patients to seek timely medical care. Advancements in diagnostic technologies and improved screening programs are also contributing to the growing demand for glaucoma therapies and management solutions.

Key growth drivers include the development of novel drug formulations, minimally invasive glaucoma surgeries (MIGS), and sustained-release treatment options that enhance patient compliance. Increasing research and development investments by pharmaceutical and medical device companies are accelerating innovation. Furthermore, improved access to ophthalmic care in emerging markets is expanding the patient base and supporting overall market growth.

Looking forward, the market is expected to benefit from technological integration in diagnostic imaging and artificial intelligence-based screening tools. Growing adoption of combination therapies and personalized treatment approaches will likely drive long-term expansion. As healthcare systems emphasize preventive eye care and early intervention strategies, the glaucoma market is poised for steady and sustainable growth globally.

Our reports are meticulously crafted to provide clients with comprehensive and actionable insights into various industries and markets. Each report encompasses several critical components to ensure a thorough understanding of the market landscape:

Market Overview: A detailed introduction to the market, including definitions, classifications, and an overview of the industry's current state.

Market Dynamics: In-depth analysis of key drivers, restraints, opportunities, and challenges influencing market growth. This section examines factors such as technological advancements, regulatory changes, and emerging trends.

Segmentation Analysis: Breakdown of the market into distinct segments based on criteria like product type, application, end-user, and geography. This analysis highlights the performance and potential of each segment.

Competitive Landscape: Comprehensive assessment of major market players, including their market share, product portfolio, strategic initiatives, and financial performance. This section provides insights into the competitive dynamics and key strategies adopted by leading companies.

Market Forecast: Projections of market size and growth trends over a specified period, based on historical data and current market conditions. This includes quantitative analyses and graphical representations to illustrate future market trajectories.

Regional Analysis: Evaluation of market performance across different geographical regions, identifying key markets and regional trends. This helps in understanding regional market dynamics and opportunities.

Emerging Trends and Opportunities: Identification of current and emerging market trends, technological innovations, and potential areas for investment. This section offers insights into future market developments and growth prospects.

MARKET SEGMENTATION

By Disease Type

• Open Angle Glaucoma
• Angle Closure Glaucoma
• Others

By Drug Class

• Prostaglandins Analogs
• Beta-blockers
• Adrenergic Agonists
• Carbonic Anhydrase Inhibitors
• Others

By Distribution Channel

• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacy

COMPANIES PROFILED

• Pfizer Inc, Santen Pharmaceutical Co Ltd, Novartis AG, Alcon Inc, Akron Operating Company LLC, Thea Pharma, AbbVie Inc, Bausch Lomb Corporation, Teva Pharmaceutical Industries Ltd, Aerie Pharmaceuticals
• We can customise the report as per your requirements.

TABLE OF CONTENTS

Chapter 1. PREFACE

• 1.1. Market Segmentation & Scope
• 1.2. Market Definition
• 1.3. Information Procurement
  • 1.3.1 Information Analysis
  • 1.3.2 Market Formulation & Data Visualization
  • 1.3.3 Data Validation & Publishing
• 1.4. Research Scope and Assumptions
  • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

• 2.1. Market Snapshot
• 2.2. Segmental Outlook
• 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

• 3.1. Market Lineage Outlook
• 3.2. Penetration & Growth Prospect Mapping
• 3.3. Value Chain Analysis
• 3.4. Regulatory Framework
  • 3.4.1 Standards & Compliance
  • 3.4.2 Regulatory Impact Analysis
• 3.5. Market Dynamics
  • 3.5.1 Market Drivers
  • 3.5.2 Market Restraints
  • 3.5.3 Market Opportunities
  • 3.5.4 Market Challenges
• 3.6. Porter's Five Forces Analysis
• 3.7. PESTLE Analysis

Chapter 4. GLOBAL GLAUCOMA MARKET: BY DISEASE TYPE 2022-2034 (USD MN)

• 4.1. Market Analysis, Insights and Forecast Disease Type
• 4.2. Open Angle Glaucoma Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.3. Angle Closure Glaucoma Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.4. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL GLAUCOMA MARKET: BY DRUG CLASS 2022-2034 (USD MN)

• 5.1. Market Analysis, Insights and Forecast Drug Class
• 5.2. Prostaglandins Analogs Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.3. Beta-blockers Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.4. Adrenergic Agonists Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.5. Carbonic Anhydrase Inhibitors Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.6. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL GLAUCOMA MARKET: BY DISTRIBUTION CHANNEL 2022-2034 (USD MN)

• 6.1. Market Analysis, Insights and Forecast Distribution Channel
• 6.2. Hospital Pharmacy Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.3. Retail Pharmacy Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.4. Online Pharmacy Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 7. GLOBAL GLAUCOMA MARKET: BY REGION 2022-2034(USD MN)

• 7.1. Regional Outlook
• 7.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.2.1 By Disease Type
  • 7.2.2 By Drug Class
  • 7.2.3 By Distribution Channel
  • 7.2.4 United States
  • 7.2.5 Canada
  • 7.2.6 Mexico
• 7.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.3.1 By Disease Type
  • 7.3.2 By Drug Class
  • 7.3.3 By Distribution Channel
  • 7.3.4 United Kingdom
  • 7.3.5 France
  • 7.3.6 Germany
  • 7.3.7 Italy
  • 7.3.8 Russia
  • 7.3.9 Rest Of Europe
• 7.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.4.1 By Disease Type
  • 7.4.2 By Drug Class
  • 7.4.3 By Distribution Channel
  • 7.4.4 India
  • 7.4.5 Japan
  • 7.4.6 South Korea
  • 7.4.7 Australia
  • 7.4.8 South East Asia
  • 7.4.9 Rest Of Asia Pacific
• 7.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.5.1 By Disease Type
  • 7.5.2 By Drug Class
  • 7.5.3 By Distribution Channel
  • 7.5.4 Brazil
  • 7.5.5 Argentina
  • 7.5.6 Peru
  • 7.5.7 Chile
  • 7.5.8 South East Asia
  • 7.5.9 Rest of Latin America
• 7.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.6.1 By Disease Type
  • 7.6.2 By Drug Class
  • 7.6.3 By Distribution Channel
  • 7.6.4 Saudi Arabia
  • 7.6.5 UAE
  • 7.6.6 Israel
  • 7.6.7 South Africa
  • 7.6.8 Rest of the Middle East And Africa

Chapter 8. COMPETITIVE LANDSCAPE

• 8.1. Recent Developments
• 8.2. Company Categorization
• 8.3. Supply Chain & Channel Partners (based on availability)
• 8.4. Market Share & Positioning Analysis (based on availability)
• 8.5. Vendor Landscape (based on availability)
• 8.6. Strategy Mapping

Chapter 9. COMPANY PROFILES OF GLOBAL GLAUCOMA INDUSTRY

• 9.1. Top Companies Market Share Analysis
• 9.2. Company Profiles
  • 9.2.1 Pfizer Inc
  • 9.2.2 Santen Pharmaceutical Co. Ltd
  • 9.2.3 Novartis AG
  • 9.2.4 Alcon Inc
  • 9.2.5 Akron Operating Company LLC
  • 9.2.6 Thea Pharma
  • 9.2.7 AbbVie Inc
  • 9.2.8 Bausch + Lomb Corporation
  • 9.2.9 Teva Pharmaceutical Industries Ltd
  • 9.2.10 Aerie Pharmaceuticals